Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis

Overview

Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-productive cough, daytime/nighttime, with duration for at least 3 and no more than 5 consecutive days (without systemic/topic use of medication during this period) followed by nasal congestion, with or without associate other nasal symptoms (sneezing, runny nose, nasal itching and/or mouth breathing). The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.

Full Title of Study: “Multicenter Clinical Trial, Phase III, Controlled, Open, Parallel Group, Randomized, Comparing the Fixed Dose Combination of Diphenhydramine + Dropropizine + Pseudoephedrine and the Combined Use of Dropropizine and Fixed Dose Combination of Pseudoephedrine Hydrochloride + Brompheniramine Maleate Used Orally for Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2 to 12 Years Old, Suffering From Non-productive Cough and Acute Rhinitis.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2012

Interventions

  • Drug: diphenhydramine + dropropizine + pseudoephedrine
    • Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup). Posology: The medicine treat will be as follows: – Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml
  • Drug: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
    • Dropropizine: Age: 2 – 3 years / Dosage: 5,0 ml Age: 4 – 12 years / Dosage: 10,0 ml Pseudoephedrine hydrochloride + brompheniramine maleate: Age: 2 – 3 years / Dosage: 2,5 ml Age: 4 – 6 years / Dosage: 5,0 ml Age: 7 – 9 years / Dosage: 7,5 ml Age: 10 – 12 years / Dosage: 10,0 ml

Arms, Groups and Cohorts

  • Experimental: Notuss® syrup
    • Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
  • Active Comparator: Dropropizine + Pseudoephedrine and brompheniramine
    • Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.

Clinical Trial Outcome Measures

Primary Measures

  • Improvement of nasal congestion and cough
    • Time Frame: Evaluated on the day 2 after beginning treatment
    • Participants were evaluated (by a parent/guardian/caregivers) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.

Secondary Measures

  • Improvement of nasal congestion and cough
    • Time Frame: Evaluated on the 7(±1) day after beginning treatment
    • Participants were evaluated (by a parent/guardian/caregivers) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.
  • Improvement of non-obstructive nasal symptoms
    • Time Frame: Evaluated on the day 2 and 7 (±1) after beginning treatment
    • Participants were evaluated (by a parent/guardian/caregivers for pain intensity by using a sum of 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.
  • Reduction of the frequency of nighttime awakenings of parent/guardian/roommate of the child
    • Time Frame: Evaluated on the day 2 and 7 (±1) after beginning treatment
  • Reduction of vomiting frequency episodes triggered by coughing
    • Time Frame: Evaluated on the day 2 and 7 (±1) after beginning treatment
  • Improvement of acute rhinitis signs
    • Time Frame: Evaluated on the day 2 and 7 (±1) after beginning treatment
    • Assessed by anterior rhinoscopy and application of specific clinical scores
  • Use of rescue medication
    • Time Frame: Evaluated on the day 2 and 7 (±1) after beginning treatment
  • Overall impression of improvement by the investigator
    • Time Frame: Evaluated on the day 2 and 7 (±1) after beginning treatment
    • Specific scale and overall impression of improvement by a parent/guardian/ caregiver of the child
  • Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
    • Time Frame: Will be evaluated during the 7(± 1) days of treatment
    • Collection of safety data throughout the whole study period

Participating in This Clinical Trial

Inclusion Criteria

1. Patients between 2 and 12 years old, of both sexes; 2. Clinical condition compatible with acute rhinitis accompanied by nasal obstruction; 3. Non-productive cough, daytime and/or nighttime with at least 3 and up 5 consecutive days in duration; 4. Score greater than or equal to 3 points on the cough severity score (As per item 4.1.2); 5. Score greater than or equal to 2 points on the nasal obstruction severity score (As per item 4.1.3); 6. ICF signed by a parent/caregiver/representant; 7. Parent/Caregiver/Representant capacity, according to investigator evaluation, for compliance at the treatment and protocol requirements, fulfilling the regular visits; Exclusion Criteria:

1. Non-productive cough with purulent smear, fever (axillar temperature superior than 37,8°C/100°F), purulent runny nose and other signs and symptoms of bacteria infection of upper and lower airways at 7 days before the screening/randomization visit; 2. Septal deviation level III (in any region and any nasal cavity) and/or nasal polyps or other determinants conditions of nasal congestion; 3. Previous diagnosis of asthma; 4. Patients under treatment for chronic allergy; 5. Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule; 6. Current use of systemic antibiotics for any reason; 7. Use of prohibited medicine within the prescribed period before V0 as shown in item 9.3 of this protocol; 8. Participation in last one year of clinical protocols; 9. Any psychiatric diseases, including major depression; 10. Presence of mental retardation from any cause; 11. Diagnosis of renal or hepatic failure; 12. History of hypersensitivity to any component of the study drugs; 13. Relatives of sponsor´s or study site´s employee; 14. Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation; 15. Patient or parent/caregiver/representant with a history of lack of compliance to treatment or previous treatment protocols; 16. Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: 12 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ache Laboratorios Farmaceuticos S.A.
  • Provider of Information About this Clinical Study
    • Carla Rosana Goulart Silva Peron, MD, Ache Laboratorios Farmaceuticos S.A

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.